



Information for Colorado Prescribers of Prescription Drugs Provided  
Pursuant to Colorado House Bill 19-1131  
*Cycle Pharmaceuticals Inc.*

| <b>NDC code</b> | <b>Marketed Prescription Drug</b>   | <b>WAC*</b> |
|-----------------|---|-------------|
| 70709-0002-60   | NITYR <sup>®</sup> (nitisinone) Tablets 2mg tablets, 60-count bottle                          | \$5,357.22  |
| 70709-0005-60   | NITYR <sup>®</sup> (nitisinone) Tablets 5mg Tablets, 60-count bottle                          | \$13,394.16 |
| 70709-0000-60   | NITYR <sup>®</sup> (nitisinone) Tablets 10mg Tablets, 60-count bottle                         | \$26,787.23 |
|                 |   |             |
| 70709-0062-30   | TASCENSO ODT <sup>®</sup> (fingolimod) 0.25 mg orally disintegrating tablets, 30-count carton | \$10,422.99 |
| 70709-0065-30   | TASCENSO ODT <sup>®</sup> (fingolimod) 0.5 mg orally disintegrating tablets, 30-count carton  | \$10,422.99 |

*Patients' out of pocket costs may differ.*

*NDC codes displayed are 11-digit codes, the additional 0 added from the 10-digit code is displayed in bold above.*

**Below please find, as applicable, generic prescription drugs\*\***

No generics of NITYR or TASCENSO ODT are available. NITYR and TASCENSO ODT are not AB rated to any other product.†

For further information please contact Cycle Vita™ by phone at +1 (888) 360-8482 or by email at [hello@cyclevita.life](mailto:hello@cyclevita.life).

\*Wholesale Acquisition Cost (WAC) represents the manufacturer's published catalog or list price for a drug product to wholesalers. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price.

\*\*The USC (Uniform System of Classification) Therapeutic Classification schema was used to determine similar generic drugs. The HCFA Drug Category of "Non-Innovator Multi-source" as supplied on the CMS (formerly HCFA) quarterly update was used to determine the generic status of the drug products. This list does not imply that the generic prescription drugs on this form are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

† FDA., 2023. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed January 3rd 2023. Available: [www.accessdata.fda.gov/scripts/cder/ob/index.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/index.cfm)

TASCENSO ODT<sup>®</sup> is a registered trademark of Handa Neuroscience, LLC. NITYR<sup>®</sup> is a registered trademark of Cycle Pharmaceuticals Ltd. Cycle Vita is a trademark of Cycle Pharmaceuticals Ltd.  
US-CC-2300004 January 2023.